Parkinson's Disease Quality of Life (PDQUALIF) - difficulty adjust change scale
General Details:
Name:
Parkinson's Disease Quality of Life (PDQUALIF) - difficulty adjust change scale
Steward:
NINDS
Definition:
Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Registration Status:
Qualified
Permissible Values:
Data Type:
Value List
Unit of Measure:
Ids:
Value
Code Name
Code
Code System
Code Description
Very
Very
Very
Moderately
Moderately
Moderately
Somewhat
Somewhat
Somewhat
Slightly
Slightly
Slightly
Not at all
Not at all
Not at all
Designations:
Designation:
Parkinson's Disease Quality of Life (PDQUALIF) - difficulty adjust change scale
Tags:
Designations:
Definition:
Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Tags:
Reference Documents:
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.